CA2373221A1 - Anticorps humains diriges contre le staphylococcus aureus - Google Patents

Anticorps humains diriges contre le staphylococcus aureus Download PDF

Info

Publication number
CA2373221A1
CA2373221A1 CA002373221A CA2373221A CA2373221A1 CA 2373221 A1 CA2373221 A1 CA 2373221A1 CA 002373221 A CA002373221 A CA 002373221A CA 2373221 A CA2373221 A CA 2373221A CA 2373221 A1 CA2373221 A1 CA 2373221A1
Authority
CA
Canada
Prior art keywords
aureus
human
antigen
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373221A
Other languages
English (en)
Inventor
Yashwant M. Deo
Tibor Keler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2373221A1 publication Critical patent/CA2373221A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps monoclonaux humains isolés et des portions de ceux-ci, de liaison à des antigènes, se liant spécifiquement à une ou plusieurs souches de <i>S. aureus</i>, y compris des souches <i>S. aureus</i> résistant à la méthicilline. Les anticorps humains peuvent être produits dans un animal transgénique non humain, par exemple, une souris transgénique, capable de produire de multiples isotypes d'anticorps monoclonaux humains par recombinaison V-D-J et commutation isotype. L'invention concerne également des compositions pharmaceutiques comprenant les anticorps humains, des animaux transgéniques non humains et des hybridomes produisant les anticorps humains. Enfin, l'invention concerne des procédés thérapeutiques et de diagnostic pour l'utilisation des anticorps humains.
CA002373221A 1999-05-03 2000-05-03 Anticorps humains diriges contre le staphylococcus aureus Abandoned CA2373221A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13221299P 1999-05-03 1999-05-03
US60/132,212 1999-05-03
PCT/US2000/012116 WO2000071585A1 (fr) 1999-05-03 2000-05-03 Anticorps humains diriges contre le staphylococcus aureus

Publications (1)

Publication Number Publication Date
CA2373221A1 true CA2373221A1 (fr) 2000-11-30

Family

ID=22452989

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373221A Abandoned CA2373221A1 (fr) 1999-05-03 2000-05-03 Anticorps humains diriges contre le staphylococcus aureus

Country Status (5)

Country Link
EP (1) EP1173485A1 (fr)
JP (1) JP2003503015A (fr)
AU (1) AU5867100A (fr)
CA (1) CA2373221A1 (fr)
WO (1) WO2000071585A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2320233A1 (fr) 2001-06-15 2011-05-11 Inhibitex, Inc. Anticorps monoclonaux et polyclonaux à réaction croisée qui reconnaissent des protéines de surface de staphylocoques à coagulase négative et de staphylocoques dores
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
US7335743B2 (en) 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
CN1787839B (zh) 2003-03-07 2011-09-28 惠氏控股公司 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物
AU2007255384B2 (en) * 2006-06-06 2012-09-27 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
EP2285831A4 (fr) * 2008-05-07 2011-05-04 Innovative Biosensors Inc Réactifs, procédés et systèmes de détection de staphylocoques résistants à la méthicilline (sarm)
KR101773368B1 (ko) 2009-04-03 2017-08-31 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
TWI469789B (zh) 2009-06-22 2015-01-21 Wyeth Llc 金黃色葡萄球菌抗原之免疫原性組合物
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
WO2011017791A1 (fr) * 2009-08-10 2011-02-17 Fundação Oswaldo Cruz ANTICORPS MONOCLONAUX POUR LA PROTÉINE PBP2a ET SÉQUENCES HOMOLOGUES POUR LE TRAITEMENT D'INFECTIONS ET L'IMMUNODIAGNOSTIC DANS DES BACTÉRIES DU PHYLUM FIRMICUTES
ES2773920T3 (es) * 2009-08-10 2020-07-15 Fundacao Oswaldo Cruz Anticuerpos monoclonales contra la proteína PBP2a y secuencias homólogas para el tratamiento de infecciones e inmunodiagnóstico de bacterias del filo Firmicutes
CN102741281B (zh) * 2009-08-10 2015-02-25 奥斯瓦道·克鲁兹基金会 PBP2-a蛋白的单克隆抗体和同源序列用于由厚壁菌门的细菌引起的免疫诊断和感染的处理
BRPI0914508B1 (pt) * 2009-08-10 2019-04-16 Fundação Oswaldo Cruz ANTICORPOS MONOCLONAIS PARA A PROTEÍNA PBP2a, E, COMPOSIÇÃO FARMACÊUTICA
CN103037885B (zh) 2010-07-02 2015-08-26 芝加哥大学 与蛋白A(SpA)变体相关的组合物和方法
KR101911229B1 (ko) 2011-08-19 2018-10-24 임모탈 스피릿 리미티드 항체 및 항체 함유 조성물
JP2014533930A (ja) * 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
JP6469094B2 (ja) 2013-05-31 2019-02-13 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
BR112015029754A2 (pt) 2013-05-31 2017-09-26 Genentech Inc anticorpos anti-teicoico da parede e conjugados
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
CN107206102A (zh) 2014-12-03 2017-09-26 豪夫迈·罗氏有限公司 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
CN107249642A (zh) * 2014-12-03 2017-10-13 豪夫迈·罗氏有限公司 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
CN111671910B (zh) * 2020-06-28 2022-04-26 兴盟生物医药(苏州)有限公司 一种抗葡萄球菌感染的联合抗体制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2625321B1 (fr) * 1987-12-24 1992-10-02 Pasteur Institut Reactif pour le diagnostic de staphylococcus aureus par agglutination
AU667460B2 (en) * 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
EP0635132B2 (fr) * 1992-03-19 2008-05-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine Anticorps opsoniques fortement reactifs, reagissant aux antigenes communs des staphylocoques
GB9415900D0 (en) * 1994-08-05 1994-09-28 Smithkline Beecham Plc Novel compounds and treatment
FR2746398B1 (fr) * 1996-03-21 1998-04-30 Bio Merieux Anticorps specifique de staphylococcus aureaus, et utilisations

Also Published As

Publication number Publication date
JP2003503015A (ja) 2003-01-28
WO2000071585A1 (fr) 2000-11-30
AU5867100A (en) 2000-12-12
EP1173485A1 (fr) 2002-01-23

Similar Documents

Publication Publication Date Title
CA2373221A1 (fr) Anticorps humains diriges contre le staphylococcus aureus
AU2002240338C1 (en) Human monoclonal antibodies to FC alpha receptor (CD89)
JP5007409B2 (ja) 樹状細胞に対するヒトモノクローナル抗体
EP1210372B1 (fr) Anticorps monoclonaux humains diriges contre her2/neu
JP4799821B2 (ja) 樹状細胞に対するヒトモノクローナル抗体
CA2450285C (fr) Anticorps monoclonaux humains diriges contre le recepteur de facteur de croissance epidermique (egfr)
AU2002240338A1 (en) Human monoclonal antibodies to FC alpha receptor (CD89)
AU2001261383A1 (en) Human monoclonal antibodies to dendritic cells
AU2002345673A1 (en) Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2004201429A1 (en) Human antibodies to staphylococcus aureus
AU2005200250B2 (en) Human monoclonal antibodies to dendritic cells
AU2006201671A1 (en) Human monoclonal antibodies to HER2/neu
ZA200209056B (en) Human monoclonal antibodies to dendritic cells.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead